, Tracking Stock Market Picks
Enter Symbol:
NuPathe Inc (PATH) [hlAlert]

Strong Buy
down 56.58 %

NuPathe Inc (PATH) rated Strong Buy with price target $7 by WBB Securities

Posted on: Tuesday,  Jan 22, 2013  8:25 AM ET by WBB Securities

WBB Securities rated Strong Buy NuPathe Inc (NASDAQ: PATH) on 01/22/2013. Previously WBB Securities rated Buy NuPathe Inc (NASDAQ: PATH) on
08/09/2010., when the stock price was $9.79. Since then, NuPathe Inc has lost 56.59% as of 02/21/2014's recent price of $4.25.
If you would have followed the previous WBB Securities's recommendation on PATH, you would have lost 56.58% of your investment in 1292 days.

NuPathe Inc. (NuPathe) is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. The Company?s product candidate, Zelrix, is a single-use patch applied to the arm or thigh for the treatment of migraine. Zelrix delivers sumatriptan through the skin in a controlled manner using its SmartRelief technology. Sumatriptan is available in oral, nasal and injectable formulations. The Company has two product candidates in preclinical development, which includes NP201 and NP202.

Research from WBB Securities provides investment professionals with up-to-date, in-depth, accurate and insightful reporting of companies that specialize in biotechnology, medical devices and healthcare. Our goal is to provide independent, straight-forward and up-to-date research so you can make educated decisions about your investments.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/22/2013 8:25 AM Buy
3.46 7.00
as of 12/13/2013
1 Week down  -0.43 %
1 Month up  13.86 %
3 Months down  -10.85 %
1 YTD down  -31.95 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/9/2010 9:25 AM Buy
9.79 12.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy